Bromocriptine, a potent dopamine D2 receptor agonist, has been shown to reduce insulin
resistance, glucose intolerance and hyperlipidaemia in both numerous animal studies and …

Aim: A high cholesterol diet (HCD) is known to cause metabolic dysregulation, oxidative
stress, cardiovascular diseases and atherogenesis. Zingerone is a pharmacologically active …

Diabetes is a global health concern that has affected almost 415 million people globally.
Bromocriptine is a dopamine D2 agonist, which is a Food and Drug Administration (FDA) …

Bromocriptine mesylate quick release formulation has recently been approved by FDA for
the treatment of diabetes mellitus. Till now it has been mainly known for its use in …

Clozapine is widely employed in the treatment of schizophrenia. Compared with that of
atypical first-generation antipsychotics, atypical second-generation antipsychotics such as …

Vincristine (VCR), a vinca alkaloid with anti-tumor and anti-oxidant properties, is acclaimed
to possess cardioprotective action. However, the molecular mechanism underlying this …

Cardiovascular diseases and dysfunctions of the reproductive system are common
complications of type 2 diabetes (T2D), and, therefore, development of new approaches for …

BACKGROUND/AIMS: Obesity is a risk factor for glucose intolerance, steatosis, and
oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have …

Hypertension is a risk factor for several cardiovascular diseases and oxidative stress
suggested to be involved in the pathophysiology. Antihypertensive drug Clonidine action in …

Introduction: Quick release bromocriptine (BROM-QR), currently approved for glycemic
control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus …